The transition from intravenous to subcutaneous infliximab in a cohort of patients with inflammatory bowel disease: results of the INESTIMABLE retrospective observational study.

IF 2.6 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in medical sciences Pub Date : 2025-10-08 DOI:10.1016/j.advms.2025.10.001

Alessia Todeschini, Andrea Geccherle, Paola Signoretto, Nicoletta Colaci, Federica Mellone, Nicoletta De Santis, Massimo Guerriero, Giuliano Barugola, Angela Variola

{"title":"The transition from intravenous to subcutaneous infliximab in a cohort of patients with inflammatory bowel disease: results of the INESTIMABLE retrospective observational study.","authors":"Alessia Todeschini, Andrea Geccherle, Paola Signoretto, Nicoletta Colaci, Federica Mellone, Nicoletta De Santis, Massimo Guerriero, Giuliano Barugola, Angela Variola","doi":"10.1016/j.advms.2025.10.001","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to present real-world data regarding the treatment of inflammatory bowel disease (IBD) with the subcutaneous (SC) formulation of the tumor necrosis factor inhibitor, infliximab.Methods: Adult IBD patients who switched from intravenous (IV) infliximab to SC infliximab were recruited for this study. Data on the efficacy of maintaining long-term remission, persistence in therapy and the safety profile were obtained from medical records and physician assessments conducted during routine clinical practice. Data on adherence to treatment schedules and patient satisfaction were collected through an ad hoc questionnaire. The duration of the follow-up was 12 months.Results: The treatment with SC infliximab was generally well-tolerated, with a persistence rate of 86.7 % at 12 months and adherence to the treatment schedule of 86.4 %. Patients reported a favorable experience with self-injections. Mild, self-limiting adverse events were observed, and inflammatory biomarkers decreased over time, suggesting maintenance of remission in most patients.Conclusions: The findings suggest that SC infliximab may be a viable option for IBD patients in remission who are eligible for switching, offering a self-administered alternative to IV therapy.","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":" ","pages":"392-400"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.advms.2025.10.001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to present real-world data regarding the treatment of inflammatory bowel disease (IBD) with the subcutaneous (SC) formulation of the tumor necrosis factor inhibitor, infliximab.

Methods: Adult IBD patients who switched from intravenous (IV) infliximab to SC infliximab were recruited for this study. Data on the efficacy of maintaining long-term remission, persistence in therapy and the safety profile were obtained from medical records and physician assessments conducted during routine clinical practice. Data on adherence to treatment schedules and patient satisfaction were collected through an ad hoc questionnaire. The duration of the follow-up was 12 months.

Results: The treatment with SC infliximab was generally well-tolerated, with a persistence rate of 86.7 % at 12 months and adherence to the treatment schedule of 86.4 %. Patients reported a favorable experience with self-injections. Mild, self-limiting adverse events were observed, and inflammatory biomarkers decreased over time, suggesting maintenance of remission in most patients.

Conclusions: The findings suggest that SC infliximab may be a viable option for IBD patients in remission who are eligible for switching, offering a self-administered alternative to IV therapy.

查看原文本刊更多论文

炎症性肠病患者从静脉注射到皮下注射英夫利昔单抗的转变：INESTIMABLE回顾性观察性研究的结果

目的：本研究旨在提供有关肿瘤坏死因子抑制剂英夫利昔单抗皮下（SC）制剂治疗炎症性肠病（IBD）的真实数据。方法：本研究招募了从静脉注射（IV）英夫利昔单抗转为SC英夫利昔单抗的成年IBD患者。关于维持长期缓解的有效性、持续治疗和安全性的数据来自常规临床实践期间进行的医疗记录和医生评估。对治疗计划的依从性和患者满意度的数据通过特别问卷收集。随访时间为12个月。结果：SC英夫利昔单抗治疗总体耐受良好，12个月的持续率为86.7%，治疗方案的依从性为86.4%。患者报告了自我注射的良好体验。观察到轻微的自限性不良事件，炎症生物标志物随着时间的推移而下降，表明大多数患者维持缓解。结论：研究结果表明，SC英夫利昔单抗可能是IBD缓解期患者的可行选择，他们有资格转换，提供了一种自我给药的替代静脉注射治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in medical sciences 医学-医学：研究与实验

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

25 days

期刊介绍： Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.